➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

TRELSTAR Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Trelstar, and when can generic versions of Trelstar launch?

Trelstar is a drug marketed by Verity and is included in three NDAs. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.

DrugPatentWatch® Generic Entry Outlook for Trelstar

Trelstar was eligible for patent challenges on June 15, 2004.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for TRELSTAR
International Patents:46
US Patents:1
Applicants:1
NDAs:3
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 9
Patent Applications: 4,176
Drug Prices: Drug price information for TRELSTAR
What excipients (inactive ingredients) are in TRELSTAR?TRELSTAR excipients list
DailyMed Link:TRELSTAR at DailyMed
Drug patent expirations by year for TRELSTAR
Drug Prices for TRELSTAR

See drug prices for TRELSTAR

DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRELSTAR
Generic Entry Date for TRELSTAR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRELSTAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 2
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2
Sir Mortimer B. Davis - Jewish General HospitalPhase 2/Phase 3

See all TRELSTAR clinical trials

US Patents and Regulatory Information for TRELSTAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 022437-001 Mar 10, 2010 RX Yes Yes   Get Started Free   Get Started Free Y   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRELSTAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 021288-001 Jun 29, 2001   Get Started Free   Get Started Free
Verity TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 022437-001 Mar 10, 2010   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Moodys
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.